Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
US9815782B2 · kind B2 · utility
1Cited by
5References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 26, 2016 |
| Grant date | Nov 14, 2017 |
| Priority date | — |
| Expiry date | Feb 26, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C323/63
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.